ATHOS KG
VC Fund
Munich, Germany
ATHOS KG is a Munich-based single-family office. ATHOS, with its roots in healthcare and life sciences, invests in teams with great scientific competence as well as technology-driven firms that take an entrepreneurial and value-based approach.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries ATHOS KG invests in
Stages ATHOS KG invests in
Countries ATHOS KG invests in
Investment Focus
Industry
- Health Care 3 (75%)
- Medical 2 (50%)
- Biotechnology 2 (50%)
- Hospital 1 (25%)
- Life Science 1 (25%)
Stage
- Series A 1 (25%)
- Series C 1 (25%)
- Secondary Market 1 (25%)
Country
- United States 2 (50%)
- France 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Doctolib
|
Doctolib is an online booking platform and management software provider for doctors in Europe working with 65 000 health practitioners, present in 1 300 health facilities. 25 million patients visit Doctolib website and mobile app every month.For doctors, Doctolib is a full-range service to improve bookings management, reduce no-show and bring newpatients to your office. For patients, Doctolib is a free online service to find a nearby health practitioner and book doctor or dentist appointments 24/24 and 7/7 within a few clicks.Founded in 2013, Doctolib is based out of Paris, France. | $346.2M / Secondary Market / Apr 02, 2026 | |
Antheia
|
Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering —reconstructing complex molecules in yeast to bring to market next-generation plant-inspired medicines. | $24M / Series C / Jan 27, 2026 | |
Bambusa Therapeutics
|
Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies. | Series A / Nov 17, 2025 | |
|
Antheia
|
Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering —reconstructing complex molecules in yeast to bring to market next-generation plant-inspired medicines. | $56M / Series C / Jun 03, 2025 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does ATHOS KG invest in?
ATHOS KG invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did ATHOS KG last invest?
The most recent investment recorded for ATHOS KG closed in Apr 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
